The Medicines Company
https://www.themedicinescompany.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From The Medicines Company
Granules’ Form 483: Trucks Full Of Documents, Deficient Maintenance, And Bird Droppings
The US FDA has issued a Form 483 to Granules India, with six observations, spanning document and vent mismanagement to bird droppings and rust.
ESMO 24: Investors Are Starting To Believe In BioNTech’s Cancer Drugs
The company’s investment in oncology is starting to pay off, with its PD-L1/VEGF inhibitor BNT324 generating particular interest at ESMO.
Merck/Daiichi Beef Up Regulatory Position For HER3 ADC
The two drug makers announced topline Phase III results for patritumab deruxtecan in EGFR-mutated NSCLC. The drug was hit by a complete response letter earlier this year.
Aiming For Keytruda’s Crown, Summit Raises Extra Funds To Fuel Ivonescimab Ambitions
The US company believes it can not only beat Keytruda at its own game, but also achieve success where Merck & Co's blockbuster and other immunotherapies have failed.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Annovation Biopharma, Inc.
- Boxford Subsidiary
- Curacyte Discovery GmbH
- Incline Therapeutics, Inc.
- ProFibrix B.V.
- Rempex Pharmaceuticals, Inc.
- Targanta Therapeutics Corporation
- Tenaxis Medical
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice